skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

How Pharma Copes with the Pain of Developing Abuse-Deterrent Opioids

With the wide availability of generic opioid analgesics, such as oxycodone and hydromorphone, the abuse of prescription opioids has become a major public health problem in the US. Consequently, in January 2013, the FDA released draft guidance for drug makers that mandates inclusion of abuse-deterrent technology for new opioid products. Data from Pharmaprojects and Trialtrove were analyzed to explore the current development for opioid analgesics with abuse-deterrent technology in order to gain insight into the front runners of this competitive area, their characteristics, and the top sponsors on the verge of becoming market leaders.

One of the most common approaches in abuse-deterrent technology is the development of new formulations of extended-release opioids, or tamper resistant properties that render the drugs difficult to crush, grind, and dissolve for injection or nasal insufflation by potential abusers.

Find out more. Download whitepaper below.


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: